Free Trial
NASDAQ:GDTC

CytoMed Therapeutics (GDTC) Stock Price, News & Analysis

CytoMed Therapeutics logo
$1.96 -0.06 (-2.74%)
Closing price 09/3/2025 03:58 PM Eastern
Extended Trading
$1.94 -0.02 (-0.77%)
As of 09/3/2025 05:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About CytoMed Therapeutics Stock (NASDAQ:GDTC)

Key Stats

Today's Range
$1.85
$2.03
50-Day Range
$1.75
$2.31
52-Week Range
$1.20
$4.05
Volume
7,302 shs
Average Volume
9,924 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Buy

Company Overview

CytoMed Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

GDTC MarketRank™: 

CytoMed Therapeutics scored higher than 46% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CytoMed Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    CytoMed Therapeutics has received no research coverage in the past 90 days.

  • Read more about CytoMed Therapeutics' stock forecast and price target.
  • Percentage of Shares Shorted

    0.86% of the float of CytoMed Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    CytoMed Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CytoMed Therapeutics has recently decreased by 2.31%, indicating that investor sentiment is improving.
  • Dividend Yield

    CytoMed Therapeutics does not currently pay a dividend.

  • Dividend Growth

    CytoMed Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.86% of the float of CytoMed Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    CytoMed Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CytoMed Therapeutics has recently decreased by 2.31%, indicating that investor sentiment is improving.
  • News Sentiment

    CytoMed Therapeutics has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for CytoMed Therapeutics this week, compared to 0 articles on an average week.
Receive GDTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytoMed Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GDTC Stock News Headlines

“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.tc pixel
See More Headlines

GDTC Stock Analysis - Frequently Asked Questions

CytoMed Therapeutics' stock was trading at $3.40 on January 1st, 2025. Since then, GDTC stock has decreased by 42.5% and is now trading at $1.9550.

CytoMed Therapeutics (GDTC) raised $10 million in an IPO on Friday, April 14th 2023. The company issued 2,412,369 shares at a price of $4.00 per share.

Shares of GDTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CytoMed Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN), AstraZeneca (AZN) and Baidu (BIDU).

Company Calendar

Today
9/03/2025
Next Earnings (Estimated)
9/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GDTC
CIK
1873093
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

High Price Target
$5.00
Low Price Target
$5.00
Potential Upside/Downside
+160.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.05
Current Ratio
9.89
Quick Ratio
9.89

Sales & Book Value

Annual Sales
$69.50 thousand
Price / Sales
302.22
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.61 per share
Price / Book
3.15

Miscellaneous

Outstanding Shares
10,940,000
Free Float
N/A
Market Cap
$21.00 million
Optionable
Not Optionable
Beta
-0.38

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:GDTC) was last updated on 9/4/2025 by MarketBeat.com Staff
From Our Partners